ASN Kidney Week 2024
Advertisement
Obinutuzumab reduced proteinuria in patients with FSGS who were treatment-resistant or on immunosuppressive therapy.
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
A study examined the efficacy of adding SZC to allow patients with stage 3-4 DKD to maintain treatment with RAASi.
Researchers assessed the safety and efficacy of bardoxolone methyl (BARD) in patients with ADPKD.
Vlado Perkovic spoke about findings from the FLOW, APPLAUSE-IgAN, and CREDENCE trials presented at ASN Kidney Week.
Researchers studied the efficacy and safety of dapagliflozin in patients with chronic kidney disease stages 4 and 5.
A study examined whether the relationship between hyponatremia and higher mortality and rehospitalization is causal.
Researchers studied risk of postoperative AKI with perioperative hypotension- versus hypertension-avoidance strategies.
Carla Nester spoke about two presentations at Kidney Week focused on potential therapies for C3 glomerulopathy.
Sagar Nigwekar discussed interim data from the SEAPORT 1 trial of INZ-701 for treatment of calciphylaxis.
Guru Reddy discussed three posters presented by Unicycive Therapeutics at ASN Kidney Week 2024, on UNI-494 and OLC.
Benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Susan Quaggin, winner of the 2024 John P. Peters Award, spoke with us about the award, her work, and ASN Kidney Week.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
Melissa Little discussed kidney regeneration and her stem cell research with Joel Topf of Nephrology Times.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.